For two years, Hikma Pharmaceuticals generously funded AT Forum. That funding ended at the end of 2022, but AT Forum still values the company’s – and all companies’ – contributions to the field. Please keep reading! Again, thank you Hikma. These have been difficult times for many in the opioid use disorder treatment field. As AATOD’s Mark Parrino told us recently, a ship at sea … [Read more...] about Thank you Hikma!
One of the public health concerns about prescription opioids, including for pain, is diversion, but injectables can help avoid those concerns. Last spring Hikma released a new generic buprenorphine injectable product indicated for pain, a generic version of Indivior’s Buprenex. For more information, go to … [Read more...] about Generic Buprenex
https://www.samhsa.gov/sites/default/files/programs_campaigns/medication_assisted/telemedicine-dea-guidance.pdf https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines/covid-19-guidance-otp https://www.samhsa.gov/sites/default/files/otp-guidance-20200316.pdf https://www.samhsa.gov/sites/default/files/sample-otp-covid-19-faqs.pdf https://w … [Read more...] about COVID-19 Resources
Conferences and Meetings, Webinars & Trainings To post your meeting, conference or webinar announcement in the AT Forum newsletter or at this website, submit it via e-mail. AT Forum reserves the right to choose which events we post. Many conferences have cancelled, are trying to reschedule, or are going “virtual” (online presentations only). Stay … [Read more...] about Events